Higher tumour-infiltrating lymphocytes predict better pathologic response in HER2-positive breast cancer

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer

Essential breast cancer medicines

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma

Black patients show inferior survival despite similar cytogenetics and treatment response

Asciminib shows high molecular response, favourable safety in 2L CML-CP